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ABSTRACT 
Systemic sclerosis (SSc) is a chronic autoimmune disease of the connective tissue. The variety and 
clinical relevance of autoantibodies in SSc patients have been extensively studied, eventually 
identifying agonistic autoantibodies targeting the platelet-derived growth factor receptor alpha 
(PDGFRα), and representing potential biomarkers for SSc.  
We used a resonant mirror biosensor to characterize the binding between surface-blocked PDGFRα 
and PDGFRα-specific recombinant human monoclonal autoantibodies (mAbs) produced by SSc B 
cells, and detect/quantify serum autoimmune IgG with binding characteristics similar to the mAbs. 
Kinetic data showed a conformation-specific, high-affinity interaction between PDGFRα and 
mAbs, with equilibrium dissociation constants in the low-to-high nanomolar range. When applied 
to total serum IgG, the assay discriminated between SSc patients and healthy controls, and allowed 
the rapid quantification of autoimmune IgG in the sera of SSc patients, with anti-PDGFRα IgG 
falling in the range 3.20-4.67 neq/L of SSc autoantibodies. The test was validated by comparison to 
direct and competitive anti-PDGFRα antibody ELISA. This biosensor assay showed higher 
sensibility with respect to ELISA, and other major advantages such as the specificity, rapidity, and 
reusability of the capturing surface, thus representing a feasible approach for the detection and 
quantification of high affinity, likely agonistic, SSc-specific anti-PDGFRα autoantibodies. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 3 
 
1. INTRODUCTION 
The term Systemic sclerosis, or scleroderma, designates a heterogeneous autoimmune connective 
tissue disease characterized by distinct clinical patterns, which often display dramatically different 
clinical outcomes as different as a long survival time with limited morbidity and a decreased 
lifespan with huge disability [1]. One of the main limitations in the clinical management of SSc 
patients, once diagnosis has been formulated, is the lack of biomarkers predicting disease evolution 
and correlating with disease activity and severity. In fact, currently available biomarkers are 
certainly useful for SSc diagnosis, sub-classification and association with organ involvement [2], 
but none of them is sensitive to disease changes. To fill this gap, our group has focused the attention 
on serum anti-PDGFRα autoantibodies characterized by possessing stimulatory activity, both in 
vitro on human cells involved in SSc pathogenesis [3, 4] and in vivo on regenerated human skin 
engrafted onto mice [5], under the hypothesis that biologically active autoantibodies may correlate 
better with disease activity. One major problem with the validation of this hypothesis was the 
inability of detecting serum anti-PDGFRα antibodies with standard methods [6-8]. Recently, this 
problem has been partly solved by identifying the PDGFRα epitopes bound by these autoantibodies. 
We discovered that distinct PDGFRα epitopes are recognized by agonistic and non-agonistic 
autoantibodies, and used the peptides corresponding to these epitopes to detect the presence of 
agonistic autoantibodies in the serum of SSc patients but not in healthy controls [9]. However, this 
method, a competitive ELISA based on molar excess of soluble peptides added to serum samples 
before PDGFRα binding detection, does not permit quantification of SSc antibodies, limiting their 
potential as biomarkers usable to dissect the different clinical phases of this chronic disease. To 
address this issue, we adapted our previously described PDGFRα biosensor [10] to measure and 
compare the reactivity of agonistic and non-agonistic human anti-PDGFRα autoantibodies cloned 
from SSc B cells, and applied the binding kinetics of the monoclonal antibody possessing higher 
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agonistic activity towards the PDGFRα to calibrate the biosensor, eventually developing a 
quantitative biosensor-based assay. We describe herein this analytical method able to rapidly and 
reliably detect and quantify anti-PDGFRα serum IgG autoantibodies with nanomolar sensitivity.  
 
2. MATERIALS AND METHODS 
2.1. Materials and devices 
CuSO4, HCl, NaOH, NaCl, KCl, NaH2PO4 were obtained from Mallinckrodt Baker (Milan, Italy). 
Tween-20, G 418 disulphate salt and SDS were from Sigma-Aldrich (Milan, Italy). Carboxylate-
functionalized cuvettes and the immobilization chemicals (N-hydroxysuccinimide (NHS), 1-ethyl-
3-(3-dimethylaminopropyl)-carbodiimide (EDC), and ethanolamine) were obtained from 
Neosensors (Crewe, UK). All chemicals were of highest purity available. 
Human PDGF-BB and mouse anti-human PDGFRα monoclonal antibody mab322 were obtained 
from R&D Systems (Milan, Italy). Fluorescein isothiocyanate labelled secondary antibody was 
obtained from Jackson Immunoresearch (PA, USA). Rabbit anti-human PDGFRα antibody D01P 
was obtained from Abnova (Taipei, Taiwan). HRP-conjugated goat anti-rabbit IgG was obtained 
from Santa Cruz (Heidelber, Germany). 
pcDNA V5 HIS A vector and Lipofectamine 2000 were obtained from Invitrogen (Milan, Italy) 
HeLa cells were obtained from ATCC (Rockville, TX, USA). 
Human PDGFRα and recombinant human monoclonal autoantibodies (mAb), namely VHPAM-
Vκ13B8, VHPAM-Vκ16F4, VHPAM-Vλ16F4, and VHPAM-Vλ13B8) were produced and purified as 
previously reported [9, 11]. 
Binding analyses were carried out on an evanescent wave/resonant mirror [12] optical biosensor 
(IAsys plus - Affinity Sensors Ltd, Cambridge, UK). The resonant mirror apparatus (consisting of a 
high-refractive-index dielectric coupling layer deposited on a silica glass prism waveguide [13], 
with a low-refractive-index hafnium oxide layer interposed) is integrated in an open two-wells 
cuvette structure, with the sensing surface being exposed to the solution contained within the 
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cuvette lumen. Soluble ligands, reagents and buffers can be added by manual pipetting, and 
removed using an integrated vacuum aspiration system. A micro-stirrer is included to ensure rapid 
sample mixing and to prevent limits due to diffusion. 
Chromatographic analyses were performed on an AKTA Basic System (GE Healthcare, Milan, 
Italy), using HiTrap metal-chelating columns obtained from GE Healthcare (Milan, Italy), and a 
Tosoh ProgelTM-TSK G2000 SWXL column, 30 cm × 7.8 mm (Sigma Aldrich, Milan, Italy).  
  
 
2.2. Immobilization of rhPDGFRα-His 
rhPDGFRα-functionalized surfaces were obtained as previously reported [10]. Briefly, carboxylate 
cuvettes were rinsed with PBS pH 7.4, and activated with an equimolar solution of EDC and NHS 
[14]. rhPDGFRα-His was solubilized in 10 mM CH3COONa buffer pH 4.5, then anchored to the 
carboxylic surface via the N-terminus of histidine tail. To achieve optimal surface density, we 
tested different rhPDGFRα concentrations in the range 100-800 µg/mL: the concentration 300 
µg/mL was finally selected as it provided an adequate number of binding sites, and at the same time 
prevented the dimerization between blocked rhPDGFRα macromolecules that could reduce the 
number of available binding sites on the sensing surface [9]. In detail, 100, 200 and 800 µg/mL 
rhPDGFRα solutions yielded to surfaces with lower sensibility (rhPDGFRα surface resulting from 
100 and 200 µg/mL solutions was characterized by lower surface density/number of binding sites 
for SSc autoantibodies; rhPDGFRα surface resulting from 800 µg/mL solution, irrespective of 
higher surface density, was characterized by a lower number of effectively available binding for 
SSc autoantibodies, both because of steric hindrance and rhPDGFRα dimerization). Next, free 
carboxylic sites on the sensor surface were blocked by injection of 1 M ethanolamine, pH 8.5. The 
surface was finally re-equilibrated with PBS (pH=7.4). Following immobilization, negative baseline 
drift signals were not observed with time or multiple PBS (pH=7.4) washes, confirming that the 
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receptor molecules were irreversibly linked to the sensor surface. The resulting shift in sensor 
response indicated the coupling of a partial ‘Langmuir’ layer (70% surface occupancy) 
corresponding to a final surface density of 1.7 ng/mm2, approximately equivalent to 7 mg/mL (see 
Supplementary Material for details). The use of CH3COONa 10 mM, pH 4.5 as immobilization 
buffer (chosen upon the PDGFRα isoelectric point=5.5) allowed an efficient immobilization, while 
preserving the native-like conformation of the receptor, as assessed by PDGF-BB and anti-
PDGFRα mab322, which can recognize only conformational binding sites of the extracellular 
PDGFRα domain. Specifically, prior to each experimental session, association kinetics were 
monitored upon independent additions of PDGF-BB and mab322 (2.50 nM each) to surface-
blocked rhPDGFRα for about 1 min (the time interval required to reach the equilibrium between 
association and dissociation events). Dissociation steps were performed with a single PBS buffer 
wash (pH=7.4), whereas the baseline corresponding to non-complexed rhPDGFRα was recovered 
by serial PBS (pH 5.5) washes (approximately 10 min). Conformational controls were randomly 
repeated during analyses of IgG samples. Local and global fit analysis of the interaction data 
generally revealed monophasic kinetics. Specifically, mono-exponential analysis of association 
curves residuals was not affected by measurable systematic errors (a bi-exponential model did not 
significantly improve the quality of the fit as judged by an F-test, 95% confidence). The biosensor 
chamber was thermostatted at 25°C throughout. 
 
2.3. Derivation of binding kinetics of PDGF-BB to rhPDGFRα-functionalized surface 
Kinetic parameters of the interaction between PDGF-BB and rhPDGFRα were determined by 
individual additions of 0.13, 0.26, 1.33 and 2.66 nM PDGF-BB (three replicates each). Association 
kinetics were followed for about 1 min (the time interval requested to reach the maximal response 
at equilibrium for the highest concentration of PDGF-BB tested). The dissociation of each complex 
was achieved with a single PBS (pH=7.4) wash (dissociation phases were followed for 1 min), 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7 
whereas baseline recovery (regeneration of non-complexed rhPDGFRα surface) was obtained with 
multiple PBS (pH 5.5). Regeneration procedure times ranged between 5 and 15 min, depending 
upon PDGF-BB concentration. 
 
2.4. Binding of recombinant human mAbs to rhPDGFRα-functionalized surface 
Recombinant human mAbs were independently added at different concentrations in the range 0.58-
16 nM onto the rhPDGFRα-coated surface, and association kinetics were routinely followed up to 
equilibrium. Dissociation steps and surface regeneration were performed by addition of fresh buffer 
(PBS pH=7.4 and pH=5.5, respectively), each time assessing the baseline recovery prior to any 
further addition of soluble recombinant human mAbs. Raw data were globally fitted to a classic 
monophasic model: 
 
  (Eq.1) 
 
where Rt is the response at time t,  
 
   (Eq.2) 
 
Rmax is the maximal response at asymptotically high concentrations of [recombinant human mAb], 
and kass and kdiss are the kinetic association and dissociation constants, respectively. Data analysis 
and fitting was performed with FAST Fit software. 
 
2.5. Serum samples 
Serum samples obtained from 8 patients with a definite diagnosis of SSc [15] and 8 healthy controls 
(HC) were selected upon previous results obtained by anti-PDGFRα antibody competitive ELISA 
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[9], choosing as many positive samples as possible, and with the most homogeneous frequency 
distributions of OD values. The clinical features of SSc patients included in this study are 
summarized in Table 1. All participants gave informed consent for use of blood samples in this 
study. Ethics committee approval document is provided as Supplemental Material. 
 
 
 
Table 1. Clinical characteristics of SSc patients. 
 
 
2.6. Purification of IgG from serum 
IgG were purified from the SSc and HC sera, selected as indicated above, using individual A/G 
resin columns (Pierce) as previously described [10]. After elution with glycine at pH 2.2 and 
neutralization with Tris buffer, the fractions containing IgG were subjected to size exclusion 
chromatography (5000 MWCO, Thermo Scientific) to remove trace amounts of contaminating 
cytokines. The absence of PDGF in IgG preparations was checked by immunoblotting with a 
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primary polyclonal rabbit anti-human PDGF-BB antibody (Abcam) with detection limit of 0.1 ng 
cytokine/200 µg IgG. IgG samples were identified with a numerical code.  
2.7. Binding of serum IgG to rhPDGFRα-functionalized biosensor 
IgG samples were individually added to the PDGFRα-functionalized surface, and each response 
kinetic was monitored up to equilibrium. The dissociation of the complexes and the regeneration of 
the PDGFRα monolayer were carried out by serial PBS washes. Each IgG sample was analysed in 
triplicate. Values falling outside the 95% confidence interval were considered significantly different 
from controls. Detection procedures were replicated on different days (n=3) both on the same and 
on different rhPDGFRα-functionalized surfaces (n=3) to assess the inter-day and the “surface-to-
surface” variability. Analyses of SSc IgG samples were always performed in triplicate. 
Additionally, the number of regeneration cycles that the sensor surface could withstand without 
significant loss of assay sensitivity and accuracy, and the stability of the sensing surface throughout 
multiple measurements were evaluated and assessed. 
 
2.8. Immunoenzymatic assays (ELISAs) 
All IgG samples were tested by direct and competitive anti-PDGFRα antibody ELISA as previously 
described [9]. A standard hyperbolic calibration curve was used to estimate the concentration of 
anti-PDGFRα antibody from absorbance units. 
 
 
2.9. Limits of Detection and Quantitation 
In compliance with the IUPAC rules [16], the limits of detection (LOD) and quantification (LOQ) 
of both ELISA and biosensor assays were calculated as three and ten times the standard deviation of 
the blank measurements, respectively. IgG purified from HC sera were used as a blank reference. 
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2.10. Statistical Analysis 
Results were expressed as mean values ± standard deviation of results obtained from at least three 
separate experiments. Statistical analysis was performed with one-way ANOVA, followed by the 
Bonferroni test using Sigma-stat 3.1 software (SPSS, Chicago, IL, USA). p values <0.05 and <0.01 
were considered statistically significant. 
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3. RESULTS 
3.1. Binding kinetics and binding specificity of recombinant human mAbs 
First, we characterized the binding of recombinant human mAbs [9] to surface-blocked rhPDGFRα, 
whose native-like folding was assessed by conformational ligands, as described in the Material and 
Methods section (Fig.1, Panel A).  
 
 
Fig.1. Conformational control check (Panel A). Overlay of association and dissociation kinetics 
of mab322 and PDGF-BB (solid lines) to a surface-blocked native-like rhPDGFRα and to a 
partially denatured counterpart (emphasized by asterisks). The fit to a standard mono-exponential 
model is plotted as dotted lines. Binding of soluble PDGF-BB to immobilized rhPDGFRα (Panel 
B). Overlay of association and dissociation kinetics measured at increasing concentrations of 
PDGF-BB (solid lines), and the fit thereof to a standard mono-exponential model (dotted lines). 
 
 
PDGF-BB bound PDGFRα with the highest affinity (KD = 0.23 ± 0.02 nM) (Fig.1, Panel B) 
compared to VHPAM-Vκ13B8, VHPAM-Vκ16F4 and VHPAM-Vλ16F4 recombinant human mAbs 
(KD = 184 ± 19 nM, 71 ± 13 nM and 17 ± 5 nM, respectively), whereas VHPAM-Vλ13B8 
recombinant human mAb did not bind to PDGFRα (Fig.2).  
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Fig.2. Binding of soluble rHumaab to immobilized rhPDGFRα. Overlay of association and 
dissociation kinetics measured at increasing concentrations of VHPAM-Vκ13B8, VHPAM-Vκ16F4, 
VHPAM-Vλ16F4 (solid lines), and the fit thereof to a standard mono-exponential model (dotted 
lines). Response upon addition of non-binding VHPAM-Vλ13B8 is reported as a control of 
specificity. 
 
 
The analysis of the association/dissociation rate constants further dissected the binding properties of 
the different ligands to PDGFRα. Specifically, the different affinities to rhPDGFRα of PDGF-BB 
and recombinant human mAbs were dependent on the 10-fold faster recognition process (kass= (3 ± 
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0.2)×107 M-1s-1) of PDGF-PDGFRα complexes compared to recombinant human mAb-PDGFRα 
complexes (all characterized by kass values ranging between (1.8 ± 0.6)×106 and (2.8 ± 0.4)×106 M-
1s-1). Conversely, differences in equilibrium constants among recombinant human mAbs were 
dependent on dissociation rate constants (kdiss = 0.035 ± 0.002 s-1, 0.02 ± 0.003 s-1, and 0.003 ± 
0.001 s-1, for VHPAM-Vκ13B8, VHPAM-Vκ16F4 and VHPAM-Vλ16F4, respectively). To further 
assess the binding specificity of the recombinant human mAbs, the assay was repeated with 
immobilized human PDGFRβ-His. The recombinant human mAbs, either used at the same 
concentration or six-fold higher, did not bind to natively folded PDGFRβ (data not shown).  
 
3.3. Calibration Curve 
Based on the high affinity for rhPDGFRα and the better confidence limits for dose-response curve 
compared with the other anti-PDGFRα recombinant human mAbs (as assessed by Student’s t-test 
applied at 95% confidence level), VHPAM-Vκ16F4 was chosen to generate a calibration curve. 
Thus, VHPAM-Vκ16F4 was added to the surface-immobilized PDGFRα-His at different 
concentrations in the range 1-10 nM (Fig.3), and association kinetics were monitored up to 
equilibrium (Req). The plot of Req versus VHPAM-Vκ16F4 concentration showed the hyperbolic 
correlation: 
 
  (Eq.3) 
 
where Rmax is the response at asymptotically high concentrations of the autoantibody. This 
calibration procedure was replicated on three different days. Under the experimental conditions 
described above, the determination of IgG at sub-saturating concentrations ([IgG] < KD) assured a 
good reproducibility of the assay on different rhPDGFRα-functionalized surfaces. Moreover, the 
reversibility of the interaction enabled the achievement of an unambiguous response upon IgG 
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binding within 2 minutes. Fit (solid line) and 95% confidence bound (dashed lines) are reported in 
Fig.3, R2 being equal to 0.9989. Best fitted values for Rmax and KD,ext were 153±20 arcsec and 35±16 
nM (the value of the KD,ext being in strong agreement with the value calculated from kinetic data). 
Calibration data were expressed throughout as equivalents of VHPAM-Vκ16F4 per litre. 
 
 
Fig.3. SSc autoantibodies calibration curve. Fit to equation 3 (solid line) and 95% confidence 
bound (dashed lines) are reported. Each experimental point was the average of three replicates 
(standard errors of the mean are shown). VHPAM-Vκ16F4 was used as external calibrator. 
 
 
To calculate SSc IgG concentrations from ELISA assay and properly compare the results with 
biosensor data, VHPAM-Vκ16F4 was used also to generate an analogous hyperbolic calibration 
curve for ELISA raw data,  
 
  (Eq.4) 
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best fitted values for Absmax,E and KD,ELISA being 5.26±1.31 absorbance units and 10.6±3.4 nM. 
 
3.4. Quantification of anti-PDGFRα antibodies in IgG purified from serum 
Different dilutions of IgG samples were evaluated to minimize background signal due to cross-
reactivity with non-SSc IgGs and decrease the biosensor response within the calibration range. 1:8 
dilution of IgG samples in PBS buffer was adopted throughout. Additionally, lower dilution factors 
were excluded as they were associated to lower discriminating ability among different SSc samples: 
in fact, the levels of anti-PDGFRα IgG in non-diluted, 1:2 and 1:4 diluted samples were closer to 
saturating values for rhPDGFRα surface (corresponding to regions of the calibration curve with 
lower slope). Moreover, the 1:8 dilution was critical in reducing the time requested for surface 
regeneration (under the adopted dilution, regeneration procedures required less than 15 min). 
Limits of detection (LOD) and quantification (LOQ) of the proposed biosensor for anti-PDGFRα 
IgG (calculated as described in the Materials and Methods Section) were 2.18 and 3.08 
nanoequivalents/litre (neq/L) of VHPAM-Vκ16F4, respectively.  
For each IgG sample, three replicates were independently tested, and each sample was analysed in 
triplicate. Using the VHPAM-Vκ16F4 calibration curve, it was possible to detect and quantify anti-
PDGFRα IgG in all the 8 SSc IgG samples (3.24-4.72 neq/L range) (Table 2A).  
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Table 2. Comparison of results obtained with direct and competitive ELISA tests on both serum and 
IgG extracts, and with the rhPDGFRα-functionalized biosensor on IgG extracts. Raw as well as 
corresponding qualitative/quantitative data for SSc (A) and HC samples (B) are provided. Data are 
presented as mean value of three measurements and standard error of the mean. *LOD and LOQ 
calculated for direct ELISA assay; **LOD and LOQ calculated for biosensor method.  
  
 
SSc7 was the only sample being on the edge of significant difference from LOQ, whereas all IgG 
samples from other patients were significantly higher than LOQ. 
Conversely, only 1 out of 8 HC IgG was positive for anti-PDGFRα IgG, but under the 
quantification threshold of the biosensor (Table 2B).  
Due to the small number of samples, all intentionally selected among patients with a more severe 
disease phenotype, any statistical comparison was of limited utility. Nevertheless, two major sub-
groups with statistically different SSc IgG content were identified (Group 1: SSc2, SSc4, SSc5 and 
SSc7; Group 2: SSc1, SSc3, SSc6 and SSc8). Concerning intra-group comparison, non-significant 
differences were observed in SSc IgG content among patients SSc1, SSc3, and SSc8. Additionally, 
SSc8 was not statistically different from SSc6. No significant difference was observed among SSc2, 
SSc4, SSc5 and SSc7.  
 
3.5. Correlation between biosensor and ELISA data 
The same IgG preparations were also tested by ELISA, both in the direct and in the competitive 
formats previously reported [9].  
Comparative analysis revealed the lower sensibility of the direct ELISA: in fact, using the VHPAM-
Vκ16F4 calibration curve, anti-PDGFRα IgG were quantified by the biosensor assay in all SSc 
samples, whereas only 5 out of 8 SSc serum samples, and 3 out of 8 SSc IgG samples were 
quantified by direct ELISA (LOD and LOQ of the direct ELISA assay values were 0.21 and 0.50 
nEq/L) (Table 2A). The competitive ELISA, potentially representing the most specific method to 
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detect agonistic anti-PDGFRα IgG in both serum and purified IgG samples, was shown to be a 
merely qualitative method, because the threshold inhibition values for the presence/absence and for 
the quantification of agonistic anti-PDGFRα IgG were 29.7% and 79.0%, respectively, indicating 
that only for absorbance reductions higher than 79% it would be possible to correctly determine 
anti-PDGFRα IgG concentration, Unfortunately, such inhibition percentage is way higher than 
what we observed in all analyzed samples.      
On the other hand, all the 8 HC IgG samples were double negative, except for HC 3 and 8 that 
tested positive by direct but not by competitive ELISA (Table 2B); interestingly, HC3 tested 
positive also by biosensor assay. 
 
3.6. Reusability and efficiency of the biosensor 
Different regeneration conditions were tested. The complete dissociation of the recombinant human 
mAb/rhPDGFRα complexes was performed by washes with both mild acidic (HCl 10 mM) and 
with buffer solutions (the PBS binding buffer, with pH set to 5.5). Using 10 mM HCl, the biosensor 
surface could be used without any loss of activity for at least 10 measurement cycles before 
significant loss of binding capacity was reported. Conversely, the sensing surface resisted to a 
higher number of experimental cycles (biosensor response did not change by more than 5% after 50 
regeneration cycles) when PBS pH=5.5 was used (KD for the antigen-antibody complex was 
approximately 50-fold higher at pH 5.5). Subsequently, the use of this buffer solution provided an 
efficient (even if slower) desorption of the ligand without degrading the immobilized receptor: in 
fact, although less aggressive than complex dissociation under acidic conditions or using chaotropic 
agents (both procedures being harmful to the preservation of binding ability, and likely to diminish 
lifetime of the immobilized molecules), this procedure required longer regeneration times. The 
reproducibility of the binding assay was dissected by comparison of the intra- and inter-day 
variability. In line with the results of surface stability evaluation, a single surface (re-used on 
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different days) could withstand a total number of approximately 50 binding events before 
experiencing a significant loss of signal (> 5%).  
Concerning the inter-day variation of the same surface, the maximal coefficients of variation (5.1% 
at 10 nM VHPAM-Vκ16F4, and 4.1% at 1 nM VHPAM-Vκ16F4, respectively) were within the 
confidence limits of the calibration curve.  
Additionally, the “surface-to-surface” variation of assay sensitivity was assessed by comparing the 
measured binding affinity of different PDGFRα surface for VHPAM-Vκ16F4. This variation was 
negligible, with KD values ranging within the experimental error, independently of the batches of 
VHPAM-Vκ16F4 (the calibrator) and of rhPDGFRα used. 
 
4. Discussion 
One of the major advantages of biosensors lies in their versatility, as they can be customized and 
efficiently used in a wide range of applications [17-20]. Specifically, biosensors (both re-usable and 
single-use) are gaining an increasing impact on clinical chemistry and diagnosis [21-26]. 
Under optimized experimental conditions [10], here we characterized the binding kinetics of a 
unique panel of recombinant human monoclonal autoantibodies with different PDGFRα epitope 
specificity and biological activity [9, 11]. Tested autoantibodies showed strong specificity 
(PDGFRβ was not recognized) as well as moderate-to-high affinity for PDGFRα. Interestingly, we 
observed an affinity range progressively increasing from the non-agonistic antibody VHPAM-
Vκ13B8 to the native ligand PDGF-BB, and we found that VHPAM-Vκ16F4 agonistic antibody, 
binding specifically to a conformational motif of the human PDGFRα largely overlapping with the 
PDGF-BB binding site [9], possessed the binding profile most similar to PDGF-BB. Based on these 
results, VHPAM-Vκ16F4 mAb was used to calibrate the biosensor for the selective detection and 
quantification of human PDGFRα-specific, high affinity, bona fide agonistic, serum IgG 
autoantibodies, like those expected to be enriched in patients affected by SSc [3]. For biosensor 
analysis, we employed IgG purified from serum, since whole serum generated an extremely high, 
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and non-interpretable response upon addition onto rhPDGFRα surface due to multiple non-specific 
protein-protein interactions, which eclipsed the signal produced by specific rhPDGFRα-SSc IgG 
recognition. The data obtained herein by applying our novel biosensor assay to 8 SSc and 8 HC IgG 
samples confirmed the presence of IgG with the aforementioned characteristics in all the SSc 
samples. This finding was corroborated by comparing the biosensor results with the data obtained 
by two ELISA methods [9]. In fact, the competitive ELISA, which detects only anti-PDGFRα 
antibodies sharing the same epitope of the calibrator antibody, confirmed in 6 out of 8 SSc IgG 
samples the positivity obtained by biosensor. Only in two SSc IgG samples (SSc 4 and 7), both 
positive by biosensor assay, the competitive ELISA was negative but the direct ELISA, which 
detects all anti-PDGFRα antibodies regardless of their agonistic activity and affinity towards the 
receptor, was positive, indicating the presence of anti-PDGFRα antibodies directed to an epitope 
different from that recognized by the calibrator antibody. This suggests that the biosensor is not 
completely specific for anti-PDGFRα antibodies sharing the same epitope of the calibrator 
antibody, still it is specific for high affinity anti-PDGFRα antibodies. On the other hand, we 
intentionally selected for this study 8 HC IgG samples with previous ambiguous serological results 
(Table 2B), in order to test the ability of our new method to identify such samples as negative, 
which was indeed the case in 7 out of 8 samples. Of these negative HC IgG samples, 6 were 
confirmed by direct ELISA. The only HC IgG testing positive by biosensor (HC3), was however 
under the biosensor quantification threshold. It was positive also by direct ELISA, but negative by 
competitive ELISA. This signal may be due to traces of high-affinity, non-agonistic anti-PDGFRα 
antibodies like VHPAM-Vκ13B8. Taken altogether, the comparison between the new biosensor 
assay and the previously described ELISAs indicates a remarkable concordance, although in a small 
sample number. Thus, this must be replicated in a larger cohort in future studies. Despite this 
limitation, the inter-assay comparison indicates that the most relevant features of the biosensor 
assay are the selective detection and the quantification of high affinity anti-PDGFRα antibodies. 
These characteristics make this assay a valuable complementary tool to the direct ELISA, or even 
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an alternative tool when screening samples for agonistic anti-PDGFRα autoantibodies only. For the 
latter aim, the biosensor seems to be better suited than the competitive ELISA previously described, 
not only for the higher sensitivity but also for the shorter assay time, the lower consumption of 
reagents, and the lower cost per single analysis (Table 3). In fact, the competitive ELISA is 
characterized by an additional step consisting in the sample pre-incubation with a soluble peptide, 
with subsequent problems in terms of assay standardization and rapidity. Nonetheless, the real-time 
monitoring of biosensor response allows to check proper folding/orientation of rhPDGFRα upon 
immobilization. 
 
 
Table 3. Comparison of costs and time associated with (direct and competitive) ELISA and the 
proposed biosensor assay (*overnight incubation required; ** two-overnight incubation required). 
 
 
Moreover, the interpretation of the ELISA data requires a not trivial analytical step consisting in the 
determination of the optimal cut-off value by ROC curve. Conversely, the biosensor provides 
unambiguous responses upon the binding of high affinity anti-PDGFRα antibodies within one 
minute. Thus, it is possible to perform a quick screening of multiple samples (collectively requiring 
about one hour for the purification of IgG from serum).  
Besides these aspects, the biosensor assay holds another major advantage towards the ELISA, that 
is the quantification ability. This feature is relevant for an assay designed to measure the levels of 
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autoantibodies in human samples as biomarkers of SSc disease. In point of fact, we intentionally 
selected for this study 8 serum/IgG samples taken from patients with a more severe disease 
phenotype, in order to test the ability of our method to detect and measure anti-PDGFRα antibody 
levels in those patients who in real life would benefit from a quantifiable biomarker, e.g. during 
therapy. Of course, it will be mandatory applying this novel biosensor assay to samples taken from 
patients at different stages of disease to assess if high affinity anti-PDGFRα antibodies are sensitive 
to disease change and are, therefore, suitable as SSc biomarkers. This would fill an important gap in 
the current management of different SSc patients’ subsets [27].  
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HIGHLIGHTS 
 
 
A platelet-derived growth factor receptor α-based biosensor is presented.  
 
High-affinity specific interactions are observed between surface-blocked receptor and 
autoantibodies. 
 
The biosensor can detect and quantify high-affinity anti-PDGFRα autoantibodies in total serum 
IgG, thus discriminating SSc patients from healthy controls.  
